Amyndas Pharmaceuticals
  • Home
  • About
    • What We Do
    • Founder’s Bio
    • Management
  • Research & Development
    • Our Focus
    • Our Pipeline
    • Clinical Trials
    • Technology
    • Selected Publications
    • Notes on Targeted Conditions
  • News
  • Contact Us
  • LinkedIn
  • Twitter
  • Home
  • About
    • What We Do
    • Founder’s Bio
    • Management
  • Research & Development
    • Our Focus
    • Our Pipeline
    • Clinical Trials
    • Technology
    • Selected Publications
    • Notes on Targeted Conditions
  • News
  • Contact Us
  • LinkedIn
  • Twitter

Contact Us


Office Locations

USA Office

630 Pine Street
Philadelphia, PA 19106
USA
T: +1 (484) 620-3236
F: +1 (610) 527-7631

e-mail: info (at) amyndas.com
              clinicaltrials (at) amyndas.com
investors (at) amyndas.com
@Amyndas

EU Office
27 Kyprou
Glyfada 16675
GREECE
T: +30 (694) 722-1847
e-mail: info (at) amyndas.com

 

Latest News

  • Business Wire: Amyndas Announces Positive Top-Line Phase 2 Results for Investigational AMY-101 in Adults With Periodontal Inflammation and Gingivitis

  • Iatronet.gr: Ελληνικό φάρμακο ανοίγει νέους δρόμους στη θεραπεία της περιοδοντίτιδας

  • Το Βήμα: Ελληνικό καινοτόμο φάρμακο για την περιοδοντίτιδα

  • Amyndas announces positive top-line Phase 2 results for investigational AMY-101 in adults with periodontal inflammation and gingivitis

 

Latest Publications

  • Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis

  • Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy

  • The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

  • Complement as a target in COVID-19?

 
 

Copyright © 2021 Amyndas Pharmaceuticals. All Rights Reserved.